Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV

Lucy F. Lee; Blanca Lupiani; Robert F. Silva; Hsing Jien Kung; Sanjay M. Reddy

doi:10.1016/j.vaccine.2008.01.046

Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV

Lucy F. Lee, Blanca Lupiani, Robert F. Silva, Hsing Jien Kung, Sanjay M. Reddy

Research output: Contribution to journal › Article › peer-review

58 Citations (Scopus)

Abstract

Marek's disease virus (MDV) encodes a basic leucine-zipper protein, Meq, that shares homology with the Jun/Fos family of transcriptional factors. Conclusive evidence that Meq is an oncogene of MDV came from recent studies of a Meq-null virus, rMd5ΔMeq. This virus replicated well in vitro, but was non-oncogenic in vivo. Further characterization of this virus in vivo indicated that the meq gene is dispensable for cytolytic infection since it replicated well in the lymphoid organs and feather follicular epithelium. Since rMd5ΔMeq virus was apathogenic for chickens, we set out to investigate whether this virus could be a good candidate vaccine. Vaccine efficacy experiments conducted in Avian Disease and Oncology Laboratory (ADOL) 15I₅ × 7₁ chickens vaccinated with rMd5ΔMeq virus or an ADOL preparation of CVI988/Rispens indicated that the Meq-null virus provided protection superior to CVI988/Rispens, the most efficacious vaccine presently available, following challenge with a very virulent (rMd5) and a very virulent plus (648A) MDV strains.

Original language	English
Pages (from-to)	1887-1892
Number of pages	6
Journal	Vaccine
Volume	26
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2008.01.046
Publication status	Published - Mar 28 2008
Externally published	Yes

Keywords

Marek's disease virus
Meq oncogene
Recombinant MDV
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.01.046

Cite this

@article{95a53543147245bb8f610042648324e3,

title = "Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV",

abstract = "Marek's disease virus (MDV) encodes a basic leucine-zipper protein, Meq, that shares homology with the Jun/Fos family of transcriptional factors. Conclusive evidence that Meq is an oncogene of MDV came from recent studies of a Meq-null virus, rMd5ΔMeq. This virus replicated well in vitro, but was non-oncogenic in vivo. Further characterization of this virus in vivo indicated that the meq gene is dispensable for cytolytic infection since it replicated well in the lymphoid organs and feather follicular epithelium. Since rMd5ΔMeq virus was apathogenic for chickens, we set out to investigate whether this virus could be a good candidate vaccine. Vaccine efficacy experiments conducted in Avian Disease and Oncology Laboratory (ADOL) 15I5 × 71 chickens vaccinated with rMd5ΔMeq virus or an ADOL preparation of CVI988/Rispens indicated that the Meq-null virus provided protection superior to CVI988/Rispens, the most efficacious vaccine presently available, following challenge with a very virulent (rMd5) and a very virulent plus (648A) MDV strains.",

keywords = "Marek's disease virus, Meq oncogene, Recombinant MDV, Vaccine",

author = "Lee, {Lucy F.} and Blanca Lupiani and Silva, {Robert F.} and Kung, {Hsing Jien} and Reddy, {Sanjay M.}",

note = "Funding Information: We thank Mr. Barry Coulson for his excellent technical assistance. We also wish to thank Drs. Richard Witter and Larry Bacon for critical review of this manuscript. We acknowledge the support from NRI CSREES USDA grant number 2004-35204-14840 awarded to S.M.R. and B.L., and NRI CSREES USDA grant number 2006-35204-14207 to H.-J.K.",

year = "2008",

month = mar,

day = "28",

doi = "10.1016/j.vaccine.2008.01.046",

language = "English",

volume = "26",

pages = "1887--1892",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "15",

}

TY - JOUR

T1 - Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV

AU - Lee, Lucy F.

AU - Lupiani, Blanca

AU - Silva, Robert F.

AU - Kung, Hsing Jien

AU - Reddy, Sanjay M.

N1 - Funding Information: We thank Mr. Barry Coulson for his excellent technical assistance. We also wish to thank Drs. Richard Witter and Larry Bacon for critical review of this manuscript. We acknowledge the support from NRI CSREES USDA grant number 2004-35204-14840 awarded to S.M.R. and B.L., and NRI CSREES USDA grant number 2006-35204-14207 to H.-J.K.

PY - 2008/3/28

Y1 - 2008/3/28

N2 - Marek's disease virus (MDV) encodes a basic leucine-zipper protein, Meq, that shares homology with the Jun/Fos family of transcriptional factors. Conclusive evidence that Meq is an oncogene of MDV came from recent studies of a Meq-null virus, rMd5ΔMeq. This virus replicated well in vitro, but was non-oncogenic in vivo. Further characterization of this virus in vivo indicated that the meq gene is dispensable for cytolytic infection since it replicated well in the lymphoid organs and feather follicular epithelium. Since rMd5ΔMeq virus was apathogenic for chickens, we set out to investigate whether this virus could be a good candidate vaccine. Vaccine efficacy experiments conducted in Avian Disease and Oncology Laboratory (ADOL) 15I5 × 71 chickens vaccinated with rMd5ΔMeq virus or an ADOL preparation of CVI988/Rispens indicated that the Meq-null virus provided protection superior to CVI988/Rispens, the most efficacious vaccine presently available, following challenge with a very virulent (rMd5) and a very virulent plus (648A) MDV strains.

AB - Marek's disease virus (MDV) encodes a basic leucine-zipper protein, Meq, that shares homology with the Jun/Fos family of transcriptional factors. Conclusive evidence that Meq is an oncogene of MDV came from recent studies of a Meq-null virus, rMd5ΔMeq. This virus replicated well in vitro, but was non-oncogenic in vivo. Further characterization of this virus in vivo indicated that the meq gene is dispensable for cytolytic infection since it replicated well in the lymphoid organs and feather follicular epithelium. Since rMd5ΔMeq virus was apathogenic for chickens, we set out to investigate whether this virus could be a good candidate vaccine. Vaccine efficacy experiments conducted in Avian Disease and Oncology Laboratory (ADOL) 15I5 × 71 chickens vaccinated with rMd5ΔMeq virus or an ADOL preparation of CVI988/Rispens indicated that the Meq-null virus provided protection superior to CVI988/Rispens, the most efficacious vaccine presently available, following challenge with a very virulent (rMd5) and a very virulent plus (648A) MDV strains.

KW - Marek's disease virus

KW - Meq oncogene

KW - Recombinant MDV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=40849120430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849120430&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.01.046

DO - 10.1016/j.vaccine.2008.01.046

M3 - Article

C2 - 18313812

AN - SCOPUS:40849120430

SN - 0264-410X

VL - 26

SP - 1887

EP - 1892

JO - Vaccine

JF - Vaccine

IS - 15

ER -

Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this